Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Phenylbutazone
Drug ID BADD_D02631
Description A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit considerations indicate that this drug should not be employed for this disease. (From AMA Drug Evaluations Annual, 1994, p1822)
Indications and Usage For the treatment of backache and ankylosing spondylitis
Marketing Status approved; vet_approved
ATC Code M01AA01; M02AA01
DrugBank ID DB00812
KEGG ID D00510
MeSH ID D010653
PubChem ID 4781
TTD Drug ID D07VHR
NDC Product Code 51552-1562; 59348-0010; 49452-5285; 60592-909; 51927-1011; 66064-1050
UNII GN5P7K3T8S
Synonyms Phenylbutazone | Diphenylbutazone | Butazolidin | Butadione | Butadion | Butacote | Butapyrazole | Butapirazol | Fenilbutazon
Chemical Information
Molecular Formula C19H20N2O2
CAS Registry Number 50-33-9
SMILES CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Leukopenia01.02.02.001--Not Available
Lymphadenopathy01.09.01.002--Not Available
Melaena24.07.02.013; 07.12.02.004--Not Available
Mouth ulceration07.05.06.004--Not Available
Neutropenia01.02.03.004--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oedema peripheral02.05.04.007; 14.05.06.011; 08.01.07.007--
Palpitations02.11.04.012--
Pancytopenia01.03.03.003--Not Available
Periorbital oedema23.04.01.002; 10.01.05.010; 06.08.03.017--
Petechiae01.01.03.002; 24.07.06.004; 23.06.01.003--Not Available
Pruritus23.03.12.001--
Purpura24.07.06.005; 23.06.01.004; 01.01.04.003--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Rash erythematous23.03.13.029--Not Available
Rash macular23.03.13.003--Not Available
Rash maculo-papular23.03.13.004--
Rash papular23.03.13.017--Not Available
Rectal haemorrhage24.07.02.018; 07.12.03.001--
Salivary gland enlargement07.06.03.002--Not Available
Serum sickness-like reaction08.01.03.003; 10.01.03.005--Not Available
Splenomegaly01.09.02.001--Not Available
Stomatitis07.05.06.005--
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Thrombocytopenia01.08.01.002--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Toxic epidermal necrolysis10.01.01.006; 23.03.01.008; 12.03.01.015; 11.07.01.006--
Urticaria23.04.02.001; 10.01.06.001--
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages